المؤلفون: Neil J. Shah, Alexandra Della Pia, Tianmin Wu, Aquino Williams, Melinda Weber, Brittany Sinclaire, Elli Gourna Paleoudis, Adil Alaoui, Shaked Lev-Ari, Shari Adams, Jordan Kaufman, Sahil B. Parikh, Emily Tonti, Eric Muller, Michael Serzan, Divya Cheruku, Albert Lee, Aishwarya Sridhar, Benjamin (Thor) Perrin Hee, Jaeil Ahn, Andrew Pecora, Andrew Ip, Michael B. Atkins

المصدر: Cancers, Vol 16, Iss 12, p 2223 (2024)

مصطلحات موضوعية: immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), pembrolizumab, nivolumab, non-small cell lung cancer (NSCLC), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.mdpi.com/2072-6694/16/12/2223; https://doaj.org/toc/2072-6694; https://doaj.org/article/5b4b50fe37f3458ea7cc0ce68dc1645e

الاتاحة: https://doi.org/10.3390/cancers16122223
https://doaj.org/article/5b4b50fe37f3458ea7cc0ce68dc1645e

المؤلفون: Brittany A Sinclaire, Emily Tonti, Jaeil Ahn, Jordan Kaufman, Divya Cheruku, Adil Alaoui, Michael B. Atkins, Shaked lev-Ari, Andrew L. Pecora, Elli Gourna Paleoudis, Kanchi Krishnamurthy, Michael T Serzan, Andrew Ip, Eric Muller, Shari Adams, Sahil Parikh, Neil J. Shah, Shuo Wang, Aquino Williams, Melinda Weber

المصدر: Journal of Clinical Oncology. 39:2635-2635

مصطلحات موضوعية: Cancer Research, Immune system, Oncology, business.industry, Immune checkpoint inhibitors, Immunology, Medicine, Adverse effect, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::dacba4fc16a96660c5ac9308bc1a20c5
https://doi.org/10.1200/jco.2021.39.15_suppl.2635

المؤلفون: Brittany A Sinclaire, Shuo Wang, Michael T Serzan, Andrew Ip, Divya Cheruku, Emily Tonti, Neil J. Shah, Aquino Williams, Jordan Kaufman, Adil Alaoui, Elli Gourna Paleoudis, Jaeil Ahn, Sahil Parikh, Melinda Weber, Shari Adams, Michael B. Atkins, Andrew L. Pecora, Shaked lev-Ari, Eric Muller

المصدر: Journal of Clinical Oncology. 39:2641-2641

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Race (biology), business.industry, Internal medicine, Immune checkpoint inhibitors, Real world outcomes, medicine, Poor performance status, business, Cancer treatment

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::164530047f8517319e5eb525ee300a32
https://doi.org/10.1200/jco.2021.39.15_suppl.2641